WALTHAM, Mass.--(EON: Enhanced Online News)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
Leerink Partners 6th Annual Global
February 15, 2017 at 1:00pm ET
2017 RBC Capital Markets Global Healthcare Conference
February 23, 2017 at 9:30am ET
Cowen and Company 37th Annual Health Care
March 7, 2017 at 8:40am ET
The webcasts will be accessible live through the “Investors” section of the Company’s website, www.immunogen.com; a replay will be available at the same location for approximately a week.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen’s lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen’s ADC technology is used in Roche’s marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.